文献速递造血干细胞移植与细胞治疗

贝鲁舒地尔(选择性ROCK2抑制剂)二线或后续治疗激素依赖/耐药慢性GVHD的开放标签研究

An open-label study of belumosudil, a selective ROCK2 inhibitor, as second or subsequent line of therapy for steroid-dependent/steroid-resistant chronic GVHD.
PubMed 文献 · Am J Hematol · 2024-06-27

这项多中心、开放标签、单臂研究评估贝鲁舒地尔200 mg每日一次用于21例日本≥12岁激素依赖/耐药慢性GVHD患者二线或后续治疗,主要终点最佳总缓解率为85.7%(95%CI 63.7-97.0),无新的安全性问题。

要点

  • 最佳总缓解率85.7%,95%CI下限超过预设阈值25%。
  • 24周缓解持续时间率为75%,13/18例缓解者持续缓解≥20周。
  • 57.1%患者至少一次临床意义症状改善,57.1%患者记录到皮质类固醇减量。

核心结论

  • 贝鲁舒地尔200 mg每日一次用于日本激素依赖/耐药慢性GVHD患者二线或后续治疗有效,且无新的安全性问题。

研究设计与样本

  • 多中心、开放标签、单臂研究,纳入21例≥12岁日本激素依赖/耐药慢性GVHD患者,贝鲁舒地尔200 mg每日一次作为二线或后续治疗。

主要发现

  • 末例患者入组后24周最佳总缓解率为85.7%(95%CI 63.7-97.0),95%CI下限超过预设阈值25%。
  • 24周缓解持续时间率的Kaplan-Meier估计为75%(95%CI 46-90),13/18例缓解者(72.2%)持续缓解≥20周。
  • 中位至缓解时间4.1周(范围3.90-8.10),4周ORR 47.6%,24周ORR 75.0%;最佳ORR关节/筋膜80%、口腔66.7%、皮肤54.5%。
  • 57.1%患者至少一次临床意义症状改善,中位症状改善持续时间22.2周(范围4.0-51.3);57.1%患者记录到皮质类固醇减量。
  • 中位无失败生存和总生存未达到;治疗中出现不良事件发生率85.7%(最常见腹泻19.0%),其中38.1%为药物相关,无药物相关停药或死亡。

关键数值与推荐

  • 主要终点最佳总缓解率85.7%(95%CI 63.7-97.0),95%CI下限超过预设阈值25%。
  • 24周缓解持续时间率75%(95%CI 46-90);13/18例缓解者(72.2%)持续缓解≥20周。
  • 中位至缓解时间4.1周(范围3.90-8.10);4周ORR 47.6%,24周ORR 75.0%。
  • 最佳ORR:关节/筋膜80%,口腔66.7%,皮肤54.5%。
  • 57.1%患者至少一次临床意义症状改善,中位持续时间22.2周(范围4.0-51.3);57.1%患者皮质类固醇减量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Belumosudil mesylate is a selective Rho-associated coiled-coil kinase 2 inhibitor with immunomodulatory and antifibrosis effects. This multicenter, open-label, single-arm study evaluated belumosudil 200 mg once daily as second or subsequent line of therapy (LOT) in 21 Japanese patients ≥12 years of age with steroid-dependent/steroid-resistant chronic graft-versus-host disease (cGVHD). The primary endpoint of best overall response rate (ORR) at 24 weeks after enrollment of the last patient was 85.7% (95% confidence interval [CI]: 63.7-97.0), and the lower limit of the 95% CI exceeded the pre-defined threshold of 25%. The Kaplan-Meier estimate of duration of response rate at 24 weeks was 75% (95% CI: 46-90); 13/18 responders (72.2%) had a sustained response for ≥20 weeks. The median time to response was 4.1 weeks (range 3.90-8.10); ORR was 47.6% at 4 weeks and 75.0% at 24 weeks; best ORR was 80% for joints/fascia, 66.7% for the mouth, and 54.5% for skin. Overall, 57.1% of patients had clinically meaningful symptom improvement at least once; the median duration of symptom improvement was 22.2 weeks (range 4.0-51.3). Corticosteroid dose reductions were recorded for 57.1% of patients. Median failure-free and overall survival were not reached. Treatment-emergent adverse events occurred in 85.7% of patients (most commonly diarrhea, 19.0%), of which 38.1% were drug-related. There were no drug-related discontinuations or deaths. In summary, belumosudil 200 mg once daily as second or subsequent LOT in Japanese patients with steroid-dependent/steroid-resistant cGVHD was effective, with no new safety concerns.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Inamoto Y, Kato K, Kawakita T, et al. An open-label study of belumosudil, a selective ROCK2 inhibitor, as second or subsequent line of therapy for steroid-dependent/steroid-resistant chronic GVHD. Am J Hematol. 2024. PMID: 38934629. doi:10.1002/ajh.27424

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。